{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:36:15Z","timestamp":1793813775865,"version":"4.6.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor that is prevalent among children and adolescents. Surgery is the most important therapeutic approach for IMT and complete resection is recommended. Although 50% of IMTs show anaplastic lymphoma kinase (ALK) rearrangements, crizotinib has proven an effective therapeutic approach. However, the genetic landscape of this tumor is still not fully understood and treatment options are limited, especially in the majority of ALK-negative tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We describe the clinical case of a healthy 18-year-old female in whom a pulmonary nodule was incidentally detected<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Following a small increase in the size of the nodule, the patient underwent both <jats:sup>18<\/jats:sup>FDG-PET\/CT and <jats:sup>68<\/jats:sup>Ga-PET\/CT, resulting in a suspicion of bronchial hamartoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient underwent surgery and a salivary gland-like lung tumor was diagnosed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After surgery, the patient was referred to our cancer center, where a review of the histology slides gave a final diagnosis of ALK-negative lung IMT. Given the histology, it was decided not to administer adjuvant therapy and the patient was placed in a 3-monthly follow-up program. The patient is still disease-free 2\u200ayears post-surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Although there is no standard of care for the treatment of IMT, identifying genomic alterations could help to redefine the management of patients with negative-ALK disease. Our review of the literature on IMT and other kinase fusions revealed, in addition to ALK rearrangements, the potential association of ROS1, NTRK, RET, or PDGFR beta alterations with the tumor.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025972","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T15:02:08Z","timestamp":1621350128000},"page":"e25972","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["ALK-negative lung inflammatory myofibroblastic tumor in a young adult"],"prefix":"10.1097","volume":"100","author":[{"given":"Silvia Angela","family":"Debonis","sequence":"first","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pieri","sequence":"additional","affiliation":[{"name":"Pathology Unit, \u201cMorgagni-Pierantoni\u201d Hospital, Forl\u00ec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fausti","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"De Vita","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Riva","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Gurrieri","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vanni","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danila","family":"Diano","sequence":"additional","affiliation":[{"name":"Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mercatali","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori,\u201d Meldola"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jcp.2007.049387","article-title":"Inflammatory myofibroblastic tumors: where are we now?","volume":"61","author":"Gleason","year":"2008","journal-title":"J Clin Pathol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.pas.0000213393.57322.c7","article-title":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","volume":"31","author":"Coffin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0003-4975(99)00155-1","article-title":"Inflammatory pseudotumors of the lung","volume":"67","author":"Cerfolio","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/sj.onc.1201062","article-title":"ALK, the chromosome 2 gene locus altered by the t (2;5) in non-Hodgkin lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)","volume":"14","author":"Morris","year":"1997","journal-title":"Oncogene"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/00000478-200106000-00007","article-title":"Anaplastic lymphoma kinase expression in inflammatory pseudotumors","volume":"25","author":"Chan","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/modpathol.2010.226","article-title":"IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?","volume":"24","author":"Saab","year":"2011","journal-title":"Mod Pathol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1002\/pbc.26920","article-title":"Crizotinib in ALK+ inflammatory myofibroblastic tumors-current experience and future perspectives","volume":"65","author":"Theilen","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2016.07.002","article-title":"Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity","volume":"99","author":"Ono","year":"2016","journal-title":"Lung Cancer"},{"key":"R12-20250504","first-page":"908","article-title":"Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm?","volume":"7","author":"Panagiotopoulos","year":"2015","journal-title":"J Thorac Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/15513810801893421","article-title":"Inflammatory myofibroblastic tumor of the midesophagus","volume":"26","author":"Goldin","year":"2007","journal-title":"Fetal Pediatr Pathol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"479","DOI":"10.12659\/PJR.894902","article-title":"Inflammatory myofibroblastic tumor of the lung: unusual imaging findings of three cases","volume":"80","author":"Ufuk","year":"2015","journal-title":"Pol J Radiol"},{"key":"R15-20250504","first-page":"543","article-title":"Abdominal inflammatory myofibroblastic tumor: report on four cases and review of literature","volume":"21","author":"Mirshemirani","year":"2011","journal-title":"Iran J Pediatr"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40792-019-0674-x","article-title":"Successful treatment based on molecular biological assessment of invasive anaplastic lymphoma kinase-positive inflammatory myofibroblastic tumor of the lung","volume":"5","author":"Watanabe","year":"2019","journal-title":"Surg Case Rep"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00043426-200302000-00014","article-title":"Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy","volume":"25","author":"Dishop","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MPH.0b013e3182915cef","article-title":"Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib","volume":"35","author":"Johnson","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000090033","article-title":"IgG4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis, and retroperitoneal fibrosis with lymphadenopathy","volume":"6","author":"Kamisawa","year":"2006","journal-title":"Pancreatology"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/15384047.2015.1095407","article-title":"Anaplastic lymphoma kinase: role in cancer and therapy perspective","volume":"16","author":"Zhao","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/01.LAB.0000088856.49388.EA","article-title":"Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor","volume":"83","author":"Debelenko","year":"2003","journal-title":"Lab Invest"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/gcc.10033","article-title":"Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor","volume":"34","author":"Lovly","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"issue":"(suppl 15)","key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.2017.35.15_suppl.1538","article-title":"A clinical and genomic profile of inflammatory myofibroblastic tumors","volume":"35","author":"Daniel","year":"2017","journal-title":"J Clin Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2018.12.016","article-title":"Case report: crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor","volume":"128","author":"Mai","year":"2019","journal-title":"Lung Cancer"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/modpathol.2014.165","article-title":"Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors","volume":"28","author":"Hornick","year":"2015","journal-title":"Mod Pathol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/15384047.2018.1480290","article-title":"Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm","volume":"19","author":"He","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:21:45Z","timestamp":1746339705000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025972"}},"subtitle":["A case report and literature review of molecular alterations"],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":28,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025972","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"2021-03-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}